false
0000822370
0000822370
2026-11-18
2026-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 18, 2026
Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-35527 |
|
87-0419387 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
| 21250 Hawthorne Boulevard, Suite 800, Torrance, CA |
|
90503 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code (310) 214-0065
(Former name or former address, if changed, since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
| None |
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operation and Financial Condition.
On November 18, 2026, Emmaus
Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued
a press release announcing our results of operations and financial condition as of and for the three and nine months ended September 30,
2026, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference.
The
information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
See the accompanying Index to Exhibits, which is
incorporated herein by reference.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Date: November 18, 2026 |
Emmaus Life Sciences, Inc. |
| |
|
|
| |
By: |
/s/ WILLIS LEE |
| |
|
Name: |
Willis Lee |
| |
|
Title: |
Chairman and Chief Executive Officer |
INDEX TO EXHIBITS
Exhibit
Number |
|
Description |
| 99.1 |
|
Press release dated November 18, 2026 |
| 104 |
|
Cover Page Interactive Date File (embedded within Inline XBRL document) |
Exhibit 99.1

Emmaus Life Sciences Reports Quarterly Financial
Results
Torrance CA, November 18, 2026 - Emmaus Life
Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today
reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2026.
Highlights
“Our global net revenues declined for the
three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as
our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026.” commented Willis Lee, Chairman and Chief
Executive Officer of Emmaus. “The decline was partially offset by a related reduction in our operating expenses. Management believes
that the conflict in the Midde East also adversely affected net revenues in the region,” he added.
Financial and Operating Results
Net Revenues. Net revenues for the three
months ended September 30, 2026 were $1.9 million, compared to $3.4 million in the same period in 2025 driven by lower direct sales of
Endari® following the company’s execution of the License Agreement with NIT.
Operating Expenses. Total operating expenses
for the three months were $1.9 million compared to $2.4 million in the comparable period in 2025. The decrease was due primarily to decreased
expenses attributable to the transfer of our sales force to NIT in connection with the license arrangement.
Income (Loss) From Operations. Loss from
operations for the three months was $0.4 million compared to income from operations of $0.7 million in the same period in 2025. The changes
was due to the decrease in net revenues, partially offset by lower operating expenses.
Other Expense. The company realized other expense of $4.4 million
for the three months compared to $2.2 million in the same period in 2025. The increase was primarily due to change in fair value of conversion
features derivative based upon an increase in the company’s stock price.
Net Loss. For the three months, the company
realized a net loss of $4.7 million, or $0.07 basic loss per share based on approximately 70.2 million weighted-average common shares,
compared to net loss of $2.1 million, or $0.03 basic loss per share based on approximately 63.9 million weighted-average common shares
in the comparable period in 2025. The increase in net loss was attributable primarily to the decrease in net revenues and increase in
other expense.
Liquidity and Capital Resources. At September
30, 2026, the company had cash and cash equivalents of $1.0 million, compared to $2.1 million at December 31, 2025.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage
biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce
the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States,
Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France,
the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus’ application for marketing authorization is awaiting final action
by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.
About Endari® (prescription
grade L-glutamine oral powder)
Endari®, Emmaus’ prescription
grade L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease
in adult and pediatric patients five years of age and older.
Indication
Endari® is indicated to reduce
the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Important Safety Information
The most common adverse reactions (incidence
>10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest
pain.
Adverse reactions leading to treatment discontinuation
included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari®
in pediatric patients with sickle cell disease younger than five years of age has not been established.
For more information, please see full Prescribing
Information of Endari® at: www.ENDARIrx.com/PI.
About Sickle Cell
Disease
There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more
globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an
estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1 The genetic mutation responsible
for SCD causes an individual’s red blood cells to distort into a “C” or a sickle shape, reducing their ability to transport
oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together,
which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads
to physical symptoms of incapacitating pain, tissue and organ damage, and early death.2
Forward-looking Statements
This press release contains forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking
statements are subject to numerous assumptions, risks and uncertainties which change over time, including doubt about the company’s
ability to continue as a going concern and other factors disclosed in the company’s Annual Report on Form 10-K for the year ended
December 31, 2025 filed with the SEC on March 31, 2026 and Quarterly Report on Form 10-Q filed on November 18, 2026, and actual results
may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them,
except as may be required by law.
Company Contact:
Emmaus Life Sciences, Inc.
Investor Relations
(310) 214-0065
IR@emmauslifesciences.com
| 1 | Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and
Developmental Disabilities, Centers for Disease Control and Prevention, December 2020. |
| 2 | Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for
Action -- National Academy of Sciences Press, 2020. |
(Financial Tables Follow)
Emmaus Life Sciences, Inc.
Condensed Consolidated Statement of Operations
and Comprehensive Income (Loss) (In thousands, except share and per share
amounts)
| | |
Three Months Ended September 30, | | |
Nine Months Ended
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Revenue, Net | |
$ | 1,892 | | |
$ | 3,378 | | |
$ | 10,192 | | |
$ | 8,601 | |
| Cost of Goods Sold | |
| 369 | | |
| 247 | | |
| 881 | | |
| 622 | |
| Gross Profit | |
| 1,523 | | |
| 3,131 | | |
| 9,311 | | |
| 7,979 | |
| Operating Expenses | |
| 1,892 | | |
| 2,436 | | |
| 6,712 | | |
| 8,634 | |
| Income (loss) from Operations | |
| (369 | ) | |
| 695 | | |
| 2,599 | | |
| (655 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net Loss | |
| (4,741 | ) | |
| (2,076 | ) | |
| (6,737 | ) | |
| (5,541 | ) |
| Comprehensive Loss | |
| (2,476 | ) | |
| (3,796 | ) | |
| (5,045 | ) | |
| (3,027 | ) |
| Net Loss per Share | |
$ | (0.07 | ) | |
$ | (0.03 | ) | |
$ | (0.10 | ) | |
$ | (0.09 | ) |
| Weighted Average Common Shares Outstanding | |
| 70,188,263 | | |
| 63,865,571 | | |
| 70,188,263 | | |
| 63,865,571 | |
Emmaus Life Sciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
| | |
As of | |
| | |
September 30,
2026 | | |
December 31,
2025 | |
| Assets | |
| | |
| |
| Current Assets: | |
| | |
| |
| Cash and cash equivalents | |
$ | 971 | | |
$ | 2,127 | |
| Accounts receivable, net | |
| 1,516 | | |
| 2,804 | |
| Inventories, net | |
| 1,417 | | |
| 1,555 | |
| Prepaid expenses and other current assets | |
| 777 | | |
| 1,260 | |
| Total Current Assets | |
| 4,681 | | |
| 7,746 | |
| Property and Equipment, net | |
| 73 | | |
| 113 | |
| Right of use assets | |
| 771 | | |
| 766 | |
| Investment in convertible bond | |
| 10,994 | | |
| 12,604 | |
| Investment in equity security | |
| 989 | | |
| - | |
| Other Assets | |
| 227 | | |
| 207 | |
| Total Assets | |
$ | 17,735 | | |
$ | 21,436 | |
| | |
| | | |
| | |
| Liabilities and Stockholders’ Deficit | |
| | | |
| | |
| Current Liabilities: | |
| | | |
| | |
| Accounts payable and accrued expenses | |
$ | 25,394 | | |
$ | 22,615 | |
| Operating lease liabilities, current portion | |
| 401 | | |
| 348 | |
| Conversion feature derivative, notes payable | |
| 3,247 | | |
| - | |
| Notes payable, current portion | |
| 11,256 | | |
| 11,151 | |
| Convertible notes payable, net of discount | |
| 17,309 | | |
| 17,380 | |
| Other current liabilities | |
| 15,279 | | |
| 17,578 | |
| Total Current Liabilities | |
| 72,886 | | |
| 69,072 | |
| Other long-term liabilities | |
| 13,501 | | |
| 15,972 | |
| Total Liabilities | |
| 86,387 | | |
| 85,044 | |
| Stockholders’ Deficit | |
| (68,652 | ) | |
| (63,608 | ) |
| Total Liabilities & Stockholders’ Deficit | |
$ | 17,735 | | |
$ | 21,436 | |